Evaluating the Safety and Efficacy of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Evidence to Date

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s214870
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Efficacy and Safety of Thalidomide in Patients With Hepatocellular Carcinoma

World Journal of Gastroenterology
MedicineGastroenterology
2006English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis

Journal of Hepatology
Hepatology
2019English

Efficacy and Safety of TACE in Combination With Sorafenib for the Treatment of TACE-refractory Advanced Hepatocellular Carcinoma in Chinese Patients: A Retrospective Study

OncoTargets and Therapy
OncologyPharmacology
2017English

Efficacy and Safety of Thai Herbal Recipe in Advanced Hepatocellular Carcinoma: A Pilot, Randomized, Controlled Clinical Trial

Advancement in Medicinal Plant Research
2019English

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2017English

Safety and Efficacy of Transcatheter Arterial Chemoembolization With Embospheres in Treatment of Hepatocellular Carcinoma

Journal of Digestive Diseases
Gastroenterology
2017English

1302pdifct-1502 CLINIVO: Real-Life Experience With Nivolumab in 600 Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): Efficacy and Safety of Nivolumab and Post-Nivolumab Treatment in the French Expanded Access Program (EAP)

Annals of Oncology
MedicineOncologyHematology
2017English

Phase 2 Study of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Journal of Gastroenterology
Gastroenterology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy